Kristie L. Kahl

Cancer Network

Targeted Therapy First Strategy Reduces Need for Chemotherapy in Newly Diagnosed LBCL

By: Kristie L. Kahl

Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone may allow 57% of patients with newly diagnosed LBCL to receive less than the standard number of chemotherapy cycles without compromising curative potential.

Targeted Oncology

Smart Stop Trial: Targeted Therapy Cuts Chemo in LBCL

By: Kristie L. Kahl, Kristi Rosa

Targeted therapy-first approach in LBCL may reduce chemotherapy need, maintaining high response rates and durability.

CURE Media Group

Rybrevant Faspro FDA-Approved as First Sub-Q Therapy for EGFR NSCLC

By: Ryan Scott

The FDA has granted approval to Rybrevant Faspro, the first and only subcutaneous therapy for EGFR-mutated non-small cell lung cancer.

CURE Media Group

From Diagnosis to Decision: How Guerdy Abraira Used Genomic Testing to Navigate Breast Cancer

By: Kristie L. Kahl

Following her breast cancer diagnosis, Guerdy Abraira utilized genomic testing to gain clarity on her treatment path.

Cancer Network

GLP-1 Receptor Agonists May Improve Survival, Reduce irAEs in ICI-Treated Patients

By: Kristie L. Kahl

A large real-world analysis found that concurrent GLP-1 receptor agonist use was linked to significantly improved long-term survival and lower rates of irAEs in patients receiving ICIs.

CURE Media Group

GLP-1 Drugs May Improve Survival, Reduce Side Effects in Patients Receiving Immunotherapy

By: Kristie L. Kahl

Patients with cancer taking GLP-1 drugs alongside immunotherapy had better long-term survival and fewer immune-related side effects.

Cancer Network

Perioperative Apalutamide Shifts Standard in Localized, High-Risk Prostate Cancer

By: Kristie L. Kahl

Patients were 9 times more likely to have little to no cancer remaining after their procedure with the apalutamide doublet compared with placebo plus ADT.

CURE Media Group

Addition of Opdivo/Yervoy to Chemo Lacks Survival Benefit in Advanced Gastric/GEJ Cancer

By: Kristie L. Kahl

In a phase 3 study, Opdivo plus Yervoy did not improve overall survival when combined with chemotherapy for HER2-negative gastric or GEJ cancer.

CURE Media Group

Why Patient Voices Matter: A Liver Cancer Advocate at ASCO

By: Kristie L. Kahl

Jeff Cape, a Blue Faery volunteer and HCC caregiver, shares why patient voices matter at ASCO and what he wishes every cancer patient knew.

CURE Media Group

At ASCO, Liver Cancer Advocate Urges Annual CT Scans to Catch HCC

By: Kristie L. Kahl

Kristie Kahl of CURE spoke with Nicole Wright Dirks, a volunteer with Blue Faery, a patient advocacy organization focused on liver cancer.